uses narcolepsy type 1.

Granted Priority Review by the U.S. FDA, Takeda is preparing for a U.S. commercial launch for oveporexton in the second half of 2026 and has also completed regulatory filings in Japan and China.


rusfertide:


Rusfertide is a potential firstinclass hepcidin mimetic that has demonstrated rapid, stable, and durable hematocrit control in patients with polycythemia vera, or PV, and has the potential to shift the standard of care in this blood cancer.

Granted Priority Review by the U.S. FDA, Takeda is preparing for a U.S. commercial launch for rusfertide in the second half of 2026.


zasocitinib:


Zasocitinib is poised to be a leading oral treatment option for psoriasis patients with the potential to significantly expand the oral segment in a growing psoriasis market.

Takeda is making decisive investments to support a planned regulatory filing in 2026 and a commercial launch
=*=*=*=*=*=
当前为第7/23页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页